Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Deals

Abbott to Acquire Insulin Management Firm Bigfoot Biomedical

Fineline Cube Sep 6, 2023

Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company...

Policy / Regulatory

Taizhou Port Designated as Drug Import Port by NMPA and General Administration of Customs

Fineline Cube Sep 6, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have released a...

Company

Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms

Fineline Cube Sep 6, 2023

Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the first half of 2023,...

Policy / Regulatory

Li Li Appointed as New Director of NMPA

Fineline Cube Sep 6, 2023

The State Council has released an announcement regarding appointments and dismissals within the government. Among...

Policy / Regulatory

NHSA Mandates National Standards for Medical Consumables in Basic Medical Insurance

Fineline Cube Sep 6, 2023

The National Healthcare Security Administration (NHSA) has released a notification with a focus on enhancing...

Company Deals

Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases

Fineline Cube Sep 6, 2023

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation...

Company Drug

Neurophth Biotechnology’s NFS-05 Gene Therapy Gets Australian Clinical Trial Approval for ADOA

Fineline Cube Sep 6, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that it has received clinical trial...

Company Deals

MGI Tech Partners with Eight Companies to Expand G99-Based Sequencing Applications

Fineline Cube Sep 6, 2023

China-based MGI Tech, a subsidiary of BGI Group (SHE: 300676), has entered into cooperation agreements...

Company Drug

Harbin Gloria Pharmaceuticals’ Zimberelimab Receives NMPA Approval for Cervical Cancer Treatment

Fineline Cube Sep 6, 2023

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has announced that it has received market...

Company

Janssen Appoints Cherry Huang as President of Xi’an Janssen in China Management Shake-Up

Fineline Cube Sep 6, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced a significant management...

Company Drug

Seagen and Genmab Announce Positive Phase III Results for Tivdak in Cervical Cancer

Fineline Cube Sep 5, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), and...

Company Drug

SinoMab BioScience’s Suciraslimab Files for Market Approval in China for Rheumatoid Arthritis

Fineline Cube Sep 5, 2023

Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that a market approval...

Company

Weight-Loss Drug Demand Pushes Novo Nordisk to Peak European Market Capitalization

Fineline Cube Sep 5, 2023

Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) achieved a significant milestone last week when it...

Company Legal / IP

Janssen Sues Distributors Over Counterfeit Antiretroviral Therapies in the US

Fineline Cube Sep 5, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical...

Company Drug

Columbia University Study Weighs Cost-Effectiveness of Weight-Loss Treatments for Adolescents

Fineline Cube Sep 5, 2023

Researchers at US Columbia University have published the results of a study estimating the cost-effectiveness...

Company

Shanghai Pharmaceuticals Executives Under Investigation for Serious Disciplinary Violations

Fineline Cube Sep 5, 2023

China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has disclosed that several...

Company Drug

BDgene Technology Announces Clinical Milestone for CRISPR-Cas9 Gene Therapy in HSK

Fineline Cube Sep 5, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced the conclusion of three clinical...

Company

Sanofi Announces Management Restructuring with New Leadership Roles in China

Fineline Cube Sep 5, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced a significant restructuring of its management structure...

Company Deals

ImmuneOnco Biopharmaceuticals Begins Trading on HKEX with Successful IPO

Fineline Cube Sep 5, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) marked its debut on the Hong Kong Stock...

Company Drug

Sihuan Pharmaceutical’s Birociclib NDA Accepted for Review by China’s NMPA

Fineline Cube Sep 5, 2023

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that the National Medical Products...

Posts pagination

1 … 425 426 427 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.